These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16148113)

  • 21. Exosomes as potent cell-free peptide-based vaccine. I. Dendritic cell-derived exosomes transfer functional MHC class I/peptide complexes to dendritic cells.
    André F; Chaput N; Schartz NE; Flament C; Aubert N; Bernard J; Lemonnier F; Raposo G; Escudier B; Hsu DH; Tursz T; Amigorena S; Angevin E; Zitvogel L
    J Immunol; 2004 Feb; 172(4):2126-36. PubMed ID: 14764678
    [TBL] [Abstract][Full Text] [Related]  

  • 22. CpG oligonucleotides with modified termini and nicked dumbbell structure show enhanced immunostimulatory activity.
    Narayanan S; Dalpke AH; Siegmund K; Heeg K; Richert C
    J Med Chem; 2003 Nov; 46(23):5031-44. PubMed ID: 14584953
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Binding immune-stimulating oligonucleotides to cationic peptides from viral core antigen enhances their potency as adjuvants.
    Riedl P; Buschle M; Reimann J; Schirmbeck R
    Eur J Immunol; 2002 Jun; 32(6):1709-16. PubMed ID: 12115654
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunostimulatory CpG motifs induce CTL responses to HIV type I oligomeric gp140 envelope protein.
    Rao M; Matyas GR; Vancott TC; Birx DL; Alving CR
    Immunol Cell Biol; 2004 Oct; 82(5):523-30. PubMed ID: 15479438
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Epicutaneous application of CpG oligodeoxynucleotides with peptide or protein antigen promotes the generation of CTL.
    Klimuk SK; Najar HM; Semple SC; Aslanian S; Dutz JP
    J Invest Dermatol; 2004 Apr; 122(4):1042-9. PubMed ID: 15102096
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CpG-DNA activates in vivo T cell epitope presenting dendritic cells to trigger protective antiviral cytotoxic T cell responses.
    Vabulas RM; Pircher H; Lipford GB; Häcker H; Wagner H
    J Immunol; 2000 Mar; 164(5):2372-8. PubMed ID: 10679072
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Liposome-encapsulated CpG oligodeoxynucleotides as a potent adjuvant for inducing type 1 innate immunity.
    Suzuki Y; Wakita D; Chamoto K; Narita Y; Tsuji T; Takeshima T; Gyobu H; Kawarada Y; Kondo S; Akira S; Katoh H; Ikeda H; Nishimura T
    Cancer Res; 2004 Dec; 64(23):8754-60. PubMed ID: 15574787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A novel emulsion-type adjuvant containing CpG oligodeoxynucleotides enhances CD8+ T-cell-mediated anti-tumor immunity.
    Song YC; Cheng HY; Leng CH; Chiang SK; Lin CW; Chong P; Huang MH; Liu SJ
    J Control Release; 2014 Jan; 173():158-65. PubMed ID: 24177312
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immunostimulatory CpG-DNA and PSA-peptide vaccination elicits profound cytotoxic T cell responses.
    Maurer T; Pournaras C; Aguilar-Pimentel JA; Thalgott M; Horn T; Heck M; Heit A; Kuebler H; Gschwend JE; Nawroth R
    Urol Oncol; 2013 Oct; 31(7):1395-401. PubMed ID: 21982682
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphodiester CpG oligonucleotides as adjuvants: polyguanosine runs enhance cellular uptake and improve immunostimulative activity of phosphodiester CpG oligonucleotides in vitro and in vivo.
    Dalpke AH; Zimmermann S; Albrecht I; Heeg K
    Immunology; 2002 May; 106(1):102-12. PubMed ID: 11972638
    [TBL] [Abstract][Full Text] [Related]  

  • 31. CpG-DNA aided cross-presentation of soluble antigens by dendritic cells.
    Maurer T; Heit A; Hochrein H; Ampenberger F; O'Keeffe M; Bauer S; Lipford GB; Vabulas RM; Wagner H
    Eur J Immunol; 2002 Aug; 32(8):2356-64. PubMed ID: 12209649
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cationic carbon nanotubes bind to CpG oligodeoxynucleotides and enhance their immunostimulatory properties.
    Bianco A; Hoebeke J; Godefroy S; Chaloin O; Pantarotto D; Briand JP; Muller S; Prato M; Partidos CD
    J Am Chem Soc; 2005 Jan; 127(1):58-9. PubMed ID: 15631447
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CpG oligodeoxinucleotides functions as an effective adjuvant in aged BALB/c mice.
    Maletto BA; Rópolo AS; Liscovsky MV; Alignani DO; Glocker M; Pistoresi-Palencia MC
    Clin Immunol; 2005 Dec; 117(3):251-61. PubMed ID: 16182607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with antigenic peptides complexed with β-glucan induces potent cytotoxic T-lymphocyte activity in combination with CpG-ODNs.
    Mochizuki S; Morishita H; Kobiyama K; Aoshi T; Ishii KJ; Sakurai K
    J Control Release; 2015 Dec; 220(Pt A):495-502. PubMed ID: 26562685
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Topical TLR9 agonists induce more efficient cross-presentation of injected protein antigen than parenteral TLR9 agonists do.
    Najar HM; Dutz JP
    Eur J Immunol; 2007 Aug; 37(8):2242-56. PubMed ID: 17634951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recognition by CD8 on cytotoxic T lymphocytes is ablated by several substitutions in the class I alpha 3 domain: CD8 and the T-cell receptor recognize the same class I molecule.
    Connolly JM; Hansen TH; Ingold AL; Potter TA
    Proc Natl Acad Sci U S A; 1990 Mar; 87(6):2137-41. PubMed ID: 2107545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Decreased cytotoxic T cell activity generated by co-administration of PSA vaccine and CpG ODN is associated with increased tumor protection in a mouse model of prostate cancer.
    Lubaroff DM; Karan D; Andrews MP; Acosta A; Abouassaly C; Sharma M; Krieg AM
    Vaccine; 2006 Aug; 24(35-36):6155-62. PubMed ID: 16876291
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of overlapping epitopes in mutant ras oncogene peptides that activate CD4+ and CD8+ T cell responses.
    Abrams SI; Stanziale SF; Lunin SD; Zaremba S; Schlom J
    Eur J Immunol; 1996 Feb; 26(2):435-43. PubMed ID: 8617315
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytotoxic-T-lymphocyte human papillomavirus type 16 E5 peptide with CpG-oligodeoxynucleotide can eliminate tumor growth in C57BL/6 mice.
    Chen YF; Lin CW; Tsao YP; Chen SL
    J Virol; 2004 Feb; 78(3):1333-43. PubMed ID: 14722288
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Influence of strong CD4 epitope on long-term virus-specific cytotoxic T cell responses induced in vivo with peptides.
    Sauzet JP; Gras-Masse H; Guillet JG; Gomard E
    Int Immunol; 1996 Apr; 8(4):457-65. PubMed ID: 8671632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.